DDInter1376 DDInter639
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.
Enasidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Enasidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ubrogepant
Enasidenib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Enasidenib {u} may lead to a major life threatening interaction when taken with {v} Rosuvastatin
Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate
Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Enasidenib may lead to a major life threatening interaction when taken with Berotralstat
Enasidenib may lead to a major life threatening interaction when taken with Rosuvastatin